Patents Examined by Nora Rooney
  • Methods and compositions for dosing of allergens
    Patent number: 9345761
    Abstract: The present invention comprises methods and compositions for immunotherapy. An aspect of the invention comprises administration of one or more allergens in compositions via oral and sublingual routes. Allergen compositions are administered in dosing intervals wherein the increase in the one or more allergens administered to the patient are provided in increasing volumes of a single concentration of at least one allergen.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: May 24, 2016
    Assignee: GREER LABORATORIES, INC.
    Inventor: Robert E. Esch
  • Methods and compositions for treating
    Patent number: 9340769
    Abstract: The disclosure provides an antigenic composition useful for immunization against P. acnes, K. pneumoniae, S. aureus, or Streptococcus pyogenes. The disclosure provides a method for producing a vaccine for preventing infection and screening agents useful for preventing infection.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: May 17, 2016
    Assignee: The Regents of the University of California
    Inventors: Richard L. Gallo, Chun-Ming Huang
  • BSA-specific antibodies
    Patent number: 9327022
    Abstract: The invention relates to antibodies specific to serum albumins. More specifically, the invention relates to camelid single domain antibodies and pentabodies binding to serum albumins of various species with various affinities.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: May 3, 2016
    Assignee: National Research Council of Canada
    Inventors: Jianbing Zhang, Wangxue Chen, C. Roger MacKenzie, Mehdi Arbabi, Shenghua Li
  • DNA sequence, and recombinant preparation of group 4 major allergens from cereals
    Patent number: 9309297
    Abstract: The present invention relates to the provision of DNA sequences of group 4 major allergens from cereals. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilized for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: April 12, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Andreas Nandy, Helmut Fiebig, Oliver Cromwell
  • Peptide, adjuvants, vaccines, and methods of use
    Patent number: 9301999
    Abstract: Provided herein are peptides that have activity as mast cell activating proteins (MCAP), as well as compositions, adjuvant compositions, vaccines, and pharmaceutical formulations that include the peptides. Also provided are methods of using the peptides, including methods for eliciting an immune response to an immunogen in a mammal upon administration.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: April 5, 2016
    Assignee: Duke University
    Inventors: Herman F. Staats, Soman N. Abraham, Salvatore Pizzo
  • Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods
    Patent number: 9296798
    Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: March 29, 2016
    Assignees: Florida State University Research Foundation, Inc., The Regents Of the University of California
    Inventors: Kenneth Roux, Shridhar Sathe, Suzanne Teuber
  • Vaccine carrier
    Patent number: 9296828
    Abstract: The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: March 29, 2016
    Assignee: BIOMAY AG
    Inventors: Rudolf Valenta, Margarete Focke-Tejkl, Birgit Linhart, Susanne Vrtala, Peter Valent, Renate Reininger, Susanne Spitzauer, Ines Swoboda, Marianne Van Hage, Hans Grönlund, Johanna Tinhofer, Kerstin Westritschnig, Theresia Popow-Kraupp
  • Immunity-inducing agent
    Patent number: 9289465
    Abstract: An immunity-inducing agent comprising as an effective ingredient(s) a polypeptide(s) selected from the polypeptides: (a) a polypeptide consisting essentially of not less than 7 consecutive amino acids in any one of the amino acid sequences shown in SEQ ID NOs:2, 4, 6, 8, 10, 12 and 44 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% with the polypeptide (a) and consisting essentially of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof; which polypeptide(s) has/have an immunity-inducing activity/activities, or as an effective ingredient(s) a recombinant vector(s) which comprise(s) a polynucleotide(s) encoding the polypeptide(s) and is/are capable of expressing the polypeptide(s) in vivo, is useful as a therapeutic and/or prophylactic agent for cancer, and/or the like.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 22, 2016
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Akira Kurihara, Fumiyoshi Okano
  • Treatment of food intolerance and food allergy with IgM
    Patent number: 9273129
    Abstract: A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: March 1, 2016
    Inventor: Michael R. Simon
  • Prostate kallikrein allergen
    Patent number: 9274114
    Abstract: Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: March 1, 2016
    Assignee: Phadia AB
    Inventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
  • Zwitterionic immunomodulators for the treatment of asthma and allergy
    Patent number: 9265790
    Abstract: Methods and products for treating and protecting against asthma and allergic conditions are provided. The methods and products are related to certain naturally occurring and synthetic zwitterionic polymers which are found to induce certain T regulatory (Treg) cells and to exert immunosuppressive effects in vitro and in vivo.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: February 23, 2016
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Arthur O. Tzianabos, Dennis L. Kasper
  • Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
    Patent number: 9265824
    Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: February 23, 2016
    Assignee: ALK-Abello A/S
    Inventors: Heather Michelle Webster, Jason Daniel Frey, Trena Larissa Repp, Craig T. Grass, David Rowles, Gary Steven Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vazquez, Juan Carlos Moreno Segura, Maria Jose Chamorro Salillas
  • Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
    Patent number: 9259464
    Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: February 16, 2016
    Assignee: ALK-Abelló A/S
    Inventors: Heather M. Webster, Jason Daniel Frey, Trena L. Repp, Craig T. Grass, David Rowles, Gary Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vazquez, Juan Carlos Moreno Segura, Maria Jose Chamorro Salillas
  • Allergen-binding IgE monoclonal antibodies and method for preparing hypoallergens
    Patent number: 9261511
    Abstract: The present invention relates to human IgE antibodies and derivatives thereof, which bind non-continuous planar allergenic epitope, such as in ?-lactoglobulin, with high affinity and specificity. The present invention also relates to processes for making and engineering such allergen binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics and immunotherapy.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: February 16, 2016
    Assignee: DESENTUM OY
    Inventors: Sirpa Jylhä, Merja Niemi, Juha Rouvinen, Marja-Leena Laukkanen, Kristiina Takkinen, Hans Söderlund, Soili Mäkinen-Kiljunen, Tari Haahtela
  • Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
    Patent number: 9248097
    Abstract: The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: February 2, 2016
    Assignee: ALK-ABELLO A/S
    Inventors: Eike Gunther Wustenberg, Eckhard-Carl Albrecht Puchert
  • Recombinantly produced allergens
    Patent number: 9243045
    Abstract: The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: January 26, 2016
    Assignee: PHADIA AB
    Inventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
  • Hypoallergenic polypeptides for the treatment of house dust mite allergy
    Patent number: 9238062
    Abstract: The present invention relates to a polypeptide comprising the amino acid sequence as shown in SEQ ID NO:9 or 7. The invention further pertains to nucleic acids encoding the polypeptide, pharmaceutical compositions and vaccines.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: January 19, 2016
    Assignee: BIOMAY AG
    Inventors: Kuan-Wei Chen, Susanne Vrtala, Rudolf Valenta
  • Identification and molecular characterisation of proteins, expressed in the salivary glands
    Patent number: 9212216
    Abstract: The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have, said polynucleotide and related polypeptide may be used in different constructions and for different applications which are also included in the present invention.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: December 15, 2015
    Assignee: BIOXODES SA
    Inventors: Edmond Godfroid, Yves Decrem, Luc Vanhamme, Alex Bollen, Gerard Leboulle
  • Allergen peptide fragments and use thereof for treatment of dust mite allergies
    Patent number: 9193773
    Abstract: The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: November 24, 2015
    Assignee: ANERGIS S.A..
    Inventors: Francois Spertini, Blaise Corthesy
  • Compositions with reduced dimer formation
    Patent number: 9180098
    Abstract: The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.
    Type: Grant
    Filed: November 27, 2009
    Date of Patent: November 10, 2015
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Paul Laidler